Regen BioPharma, Inc. Submits Utility Patent Application for Immuno-Oncology Treatment

Regen BioPharma, Inc. Submits Utility Patent Application for Immuno-Oncology Treatment

Regen Biopharma, Inc., a biotechnology company focused on discovering and developing regenerative medicine applications in the immunotherapy and stem cell space, has just announced it filed for an utility patent application with the US Patent and Trademark Office for one of its potentially groundbreaking immuno-oncology treatments that stimulates dendritic cells to boost immune responses. The patent application is backed by the company’s strong findings in the niche of dendritic cell-based therapeutics, including work by scientific advisory board member, Dr. Wei-Ping Min, a professor at the University of Western Ontario, and the acquisition of Patent No. 8,389,708.

“Our filed IND # 16200 for dCellVax leverages dendritic cells that are modified outside of the body to trigger an immune response against breast cancer.  In the newly filed patent application  we cover means of activating dendritic cells inside the body, with the hope of stimulating T cell responses to clear prostate cancer,” said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma. “Effectively treating cancer requires a multi-level attack; by leveraging ex vivo activated dendritic cells combined with means of activating dendritic cells in vivo, we anticipate synergistic tumor responses.”

Within the immune system, dendritic cells are referred to as “antigen presenting cells” and they play an essential role in activating T cells. Regen BioPharma specializes in modifying the immune system to recognize and target cancer cells, ultimately harnessing the patient’s own means to fight the disease without having to worry about debilitating side effects of traditional anti-cancer treatments, such as chemo- or radiotherapy.

“Regen BioPharma is excited about accumulation of intellectual property in its immuno-oncology program.  By protecting the inventions of our scientists we aim to not only bring new products to the market, but also to position ourselves for potential licensing and co-development transactions,” said David Koos, President, CEO and Chairman of Regen BioPharma, Inc.

In a recent study entitled “Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells” a team of researchers at the A*STAR Bioprocessing Technology Institute developed a new method to improve the industrial production of monoclonal antibodies, key players of immune therapies against cancer. The study was published in the mAbs journal.